Search research articles
Contact Us
Filters
Showing results (341-350 of 418) with videos related to
Page
of 42
Sort By:
The New England Journal of Medicine
|
June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Paul B Chapman, Axel Hauschild, Caroline Robert, et al.
The New England Journal of Medicine
|
February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S Azad, Robert J Gray, Michael J Overman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Amy S Clark, Fangxin Hong, Richard S Finn, et al.
JCO Precision Oncology
|
February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
The Lancet. Oncology
|
February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur, Paul B Chapman, Caroline Robert, et al.
Nature Immunology
|
July 31, 2019
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Cancer Discovery
|
May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Nature Immunology
|
September 26, 2019
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Cancer Discovery
|
October 10, 2013
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2
Michael P O'Connell, Katie Marchbank, Marie R Webster, et al.
Page
of 42
Search research articles
Search
Showing results (341-350 of 418) with videos related to
Sort By:
Page
of 42
The New England Journal of Medicine
|
June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Paul B Chapman, Axel Hauschild, Caroline Robert, et al.
The New England Journal of Medicine
|
February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S Azad, Robert J Gray, Michael J Overman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Amy S Clark, Fangxin Hong, Richard S Finn, et al.
JCO Precision Oncology
|
February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
The Lancet. Oncology
|
February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur, Paul B Chapman, Caroline Robert, et al.
Nature Immunology
|
July 31, 2019
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Cancer Discovery
|
May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Nature Immunology
|
September 26, 2019
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Cancer Discovery
|
October 10, 2013
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2
Michael P O'Connell, Katie Marchbank, Marie R Webster, et al.
Page
of 42